ANGIOTECH PHARMACEUTICALS INC 4
4 · ANGIOTECH PHARMACEUTICALS INC · Filed Dec 14, 2009
Insider Transaction Report
Form 4
HOWARD DAVID T
Director
Transactions
- Award
Stock Option with Tandem SAR
2009-12-10+12,500→ 167,500 totalExercise: $1.41From: 2010-01-01Exp: 2014-12-09→ Common Stock (12,500 underlying)
Footnotes (3)
- [F1]Canadian $.
- [F2]The options will start to vest effective 1/1/2010 in equal monthly installments until 6/1/2010.
- [F3]Represents the number of the Company's common shares into which the stock options are convertible. In the event that the Reporting Person elects to exercise the tandem SAR, the stock option will be canceled and the Reporting Person will be entitled to receive a number of common shares with an aggregate value equal to the product of (a) the excess of the market price of a common share on the date of exercise over the exercise price of the tandem SAR, multiplied by (b) the number of tandem SARs exercised.